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Abstract
Background: Identification of diagnostic and prognostic biomarkers is a research priority for the
improved management of pancreatic ductal adenocarcinoma (PDAC). Insulin-like growth factor binding
protein 2 (IGFBP2) and mesothelin (MSLN) have shown potential as serum biomarkers in other cancers,
but have not been adequately studied in PDAC.
Methods: Serum IGFBP2 and MSLN levels were quantified by enzyme-linked immunosorbent assay
(ELISA) in a cohort of 84 PDAC patients, 84 healthy control subjects and 40 chronic pancreatitis (ChPT)
patients. Regression models related IGFBP2 and MSLN levels to diagnosis, gender, age, stage and
survival.
Results: IGFPB2 and MSLN serum levels were diagnostic for PDAC in age-adjusted models (P = 0.032
and P = 0.002, respectively) when compared with ChPT and healthy control samples. At a 95% specificity
threshold, the sensitivity for IGFBP2 was 22% and the sensitivity for MSLN was 17%. Neither protein
approached the diagnostic accuracy of CA 19-9. However, IGFBP2 or MSLN or both correctly identified
18 of the 28 samples misidentified by CA 19-9. In age-adjusted models, neither serum IGFBP2 (P = 0.36)
nor MSLN (P = 0.29) were significant predictors of survival.
Discussion: Serum IGFBP2 and MSLN are weak diagnostic classifiers individually, but may be useful in
a diagnostic biomarker panel.
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Introduction
Pancreatic cancer accounts for 3%of new cancer diagnoses,1 but in
spite of this low incidence rate, it ranks as the fourthmost common
cause of cancermortality for bothmen andwomen annually in the
United States. The problem is onlymademore troubling by the fact
that the number of deaths per 100 000 caused by pancreatic cancer
per has not decreased significantly in 15 years.1 These distressing
statistics are in large part as a result of the difficulty in detecting and
diagnosing pancreatic cancer at a treatable stage. Pancreatic ductal
adenocarcinoma (PDAC), if detected before metastasis, has a sur-
vival rate of approximately 20%. If detection does not occur until
after metastasis, the point at which symptoms begin to be notice-
able, the survival rate plummets to 5%.2 These statistics highlight
the need for better detection methods.
Of the secreted proteins that are commonly over expressed in
PDAC,3 we identified insulin-like growth factor binding protein
2 (IGFBP2) and mesothelin (MSLN) for further analysis as
potential PDAC diagnostic and prognostic biomarkers. IGFBP2
has not been evaluated as a potential diagnostic or prognostic
biomarker for PDAC. The gene and protein exhibited an average
over expressionof 4.8-fold change inPDACandhas been studied as
a circulating biomarker in lung and liver cancers.3–5 In pancreatic
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tissue, IGFPB2 was elevated in PDAC samples, but not in chronic
pancreatitis samples.6 IGFBP2 was also elevated in pancreatic juice
from pancreatic cancer patients.7 MSLN RNA demonstrated an
average over expression of 6.4-fold change in PDAC3,8–10 and has
shown diagnostic and prognostic potential in lung, ovarian and
breast cancers.3,11–13 Owing to its role in cancer progression,12–14
includingPDAC,13–18 MSLNhasbecomea target for intervention in
mesothelin-expressing cancers.14,15,19–23 Serum MSLN has been
studied as a diagnostic marker in PDAC,24,25 however, the number
of samples evaluated was small and the protein was not assessed as
a prognostic biomarker. At the level of the gene MSLN is thought
to be co-regulated with TIMP-1,26 which has previously been iden-
tified as an effective PDAC biomarker.27
Methods
Levels of IGFBP2 and MSLN were determined in serum samples
from 84 patients with histologically or cytologically confirmed
PDAC, 84 gender-matched and age-approximated healthy control
subjects (CON), and 40 patients with chronic pancreatitis
(ChPT). Serum samples from healthy control subjects were
obtained from two sources: healthy adults accompanying index
patients and excess sera obtained from a reference library (ARUP
Laboratories) managed by the University of Utah Department of
Pathology. All blood samples were collected prior to treatment,
separated into the serum component and frozen for later analysis.
Subject characteristics are detailed in Table 1. Patient treatment
and outcomes information were obtained from a curated research
database maintained by the Pancreas Cancer Research Program at
the University of Utah. Staging information was abstracted from
patient records. Survival information was determined from the
last contact date for censored cases or patient records, local and
regional cancer registries, the Social Security Death Index or
national obituary records for deceased cases. Nine of the 84 PDAC
cases evaluated in this study were censored at the time of analysis.
Table 1 Subject demographics
Diagnosis Subject group No. cases Median age
(Range), years
Pancreatic adenocarcinoma Total 84 65.5 (44–87)
Female 40 69 (44–87)
Male 44 61.5 (47–83)
Class N0 18 64 (48–83)
Class N1 39 66 (47–87)
Class M1 25 66 (44–81)
Healthy control Total 84 63.5 (29–94)
Female 40 63 (49–94)
Male 44 64 (29–85)
Chronic pancreatitis Total 40 48 (29–80)
Female 20 46.5 (30–70)
Male 20 50 (29–80)
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Figure 1 Mean serum protein levels of insulin-like growth factor
binding protein 2 (IGFBP2) and mesothelin (MSLN). IGFBP2 (a) and
MSLN (b) were measured in serum samples obtained from healthy
control subjects (CON), patients with chronic pancreatitis (ChPT)
and pre-treatment patients with confirmed pancreatic ductal adeno-
carcinoma (PDAC). Error bars represent a standard deviation. *P =
0.069 versus CON, P = 0.0002 versus ChPT and P = 0.0022 versus
CON + ChPT. †P = 0.0003 versus CON, P = 0.042 versus ChPT and
P = 0.0002 versus CON + ChPT
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Of those, five were actively followed and four were lost to follow-
up, but had not appeared in death registries.
Serum protein levels were determined by enzyme-linked
immunosorbent assay (ELISA) (Human IGFBP2 ELISA Kit;
RayBiotech, Inc., Norcross, GA, Human Mesothelin Quantikine
ELISA Kit; R&D Systems, Inc. Minneapolis, MN, Gastrointestinal
Cancer Antigen CA 19-9 EIA Test Kit; Diagnostic Automation,
Inc., Calabasas, CA, USA). The serum samples were diluted 1:200
for IGFBP2 and 1:25 for MSLN and then assayed according to the
manufacturer’s recommended protocol. CA 19-9 levels were
measured according to the manufacturer’s recommendations,
although assays were performed using 25 μl of serum. Protein
levels were calculated by comparing absorbance readings against a
calibration curve generated from standards of known concentra-
tion. Samples that yielded readings outside the linear range of
detection were further diluted and re-evaluated.
Linear models were used to relate IGFBP2 and MSLN levels to
gender, age, stage and class. Univariate and multivariate Cox
models were employed for survival analyses. Correlation analyses
were performed to compare MSLN and TIMP-1 levels. TIMP-1
levels were previously determined in these samples.27 Receiver-
operating characteristic (ROC) curves were determined and the
area under the curve (AUC) was calculated as a comparative
measure of diagnostic accuracy. All statistical analyses were per-
formed using ‘R’ statistical computing software, version 2.15.0.28
P-values < 0.05 were considered significant.
All studies were performed with the approval of the Institu-
tional Review Board at the University of Utah.
Results
IGFBP2 and MSLN as diagnostic biomarkers
To assess the diagnostic potential of IGFBP2 and MSLN, serum
levels were determined in CON cases, ChPT cases and patients
PDAC. Serum IGFBP2 was significantly elevated in PDAC cases
(450.7 ± 301.7 ng/ml, mean ± standard deviation) when com-
pared with serum from ChPT cases (258 ± 145.1 ng/ml, P =
0.0002), but did not reach the level of significance relative to
serum from healthy control subjects (321.2 ± 285.0 ng/ml, P =
0.069). Serum IGFBP2 was significantly elevated in PDAC cases
compared with the combined CON and ChPT group (P = 0.002)
(Fig. 1a). Similarly, serum MSLN was significantly elevated in
PDAC cases (32.87 ± 17.50 ng/ml) when compared with serum
from ChPT cases (25.81 ± 12.36 ng/ml, P = 0.042) as well as
healthy control subjects (24.31 ± 13.25 ng/ml, P = 0.0003). MSLN
was significantly elevated in PDAC cases when compared with the
combined controls (P = 0.0002) (Fig. 1b). Linear models indicated
that age was also significantly related to serum protein levels when
assessed in healthy control subjects, with an increase of 8.94 ng/ml
for IGFBP2 and 0.4239 ng/ml for MSLN per year (P = 0.0017 and
P = 0.00029 for slope, respectively). The direct relationship
between protein levels and age was also evident in PDAC cases for
MSLN (0.53 ng/ml/year, P = 0.003), although the relationship did
not reach the level of significance for IGFBP2 (6.01 ng/ml/year,
P = 0.058). In spite of this age dependence, serum IGFBP2 and
MSLN remained significant predictors of PDAC diagnosis when
compared with combined controls after adjusting for age (P =
0.032 and P = 0.002, respectively). Serum protein levels of IGFBP2
(P = 0.95) and MSLN (P = 0.56) were not significantly related to
gender.
Although aggregate data demonstrated elevated IGFBP2 and
MSLN in serum from PDAC cases compared with controls, there
was substantial overlap between subject groups when individual
cases were considered (Fig. 2a,b) suggesting a limited diagnostic
utility of the individual biomarkers. At a threshold value corre-
sponding to a specificity of 95%, the sensitivity for IGFBP2 was
22% (Fig. 2a) and the sensitivity for MSLN was 17% (Fig. 2b).
Figure 2 Distribution of serum insulin-like growth factor binding protein 2 (IGFBP2) and mesothelin (MSLN) in individual samples. Each data
point represents the serum level for IGFBP2 (a) and MSLN (B) in individual healthy control subjects (CON), patients with chronic pancreatitis
(ChPT) and patients with pancreatic ductal adenocarcinoma (PDAC). A threshold value corresponding to a specificity of 95% is represented
by a green line
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Demonstrating the accuracy to discriminate PDAC from both
CON and ChPT over the full range of threshold values, the diag-
nostic strength of each protein serum level can be summarized by
the area under the ROC curve (Fig. 3). The AUC for IGFBP2 was
0.655 (Fig. 3a) and for MSLN was 0.668 (Fig. 3b). For compari-
son, CA 19-9, the most commonly used biomarker for PDAC,
yielded an AUC of 0.921 in this cohort (Fig. 3c). The 95% speci-
ficity threshold yielded a sensitivity of 76% for CA 19-9. At the
commonly used clinical threshold of 37 U/ml, CA 19-9 produced
a sensitivity of 84% and a specificity of 88%. However, of the 28
samples misidentified by CA 19-9 at the 37 U/ml threshold, 18
were correctly identified by either IGFBP2 or MSLN or both using
their respective 95% specificity threshold.
Relationship between TIMP-1 and MSLN in serum
The potential co-regulation of MSLN and TIMP-1 was examined
by comparing serum levels of each protein using univariate linear
modelling. Consistent with previous findings, both MSLN and
TIMP-1 were significantly related to diagnosis. There is no signifi-
cant relationship between serumMSLN and serumTIMP-1 values
(P = 0.22, data not shown) after adjusting for diagnosis in multi-
variate models.
IGFBP2 and MSLN as disease
progression biomarkers
To examine the correlation of biomarker with extent of disease,
serum IGFBP2 and MSLN levels were compared at different
PDAC stages (Fig. 4). Mean IGFBP2 levels increased as the stage
increased (P < 0.0001, Fig. 4a) indicating that serum IGFBP2 levels
correlated with tumour burden. MSLN levels did not change sig-
nificantly as the stage advanced (P = 0.59, Fig. 4b). Neither
IGFBP2 (P = 0.44) nor MSLN (P = 0.26) serum levels were sig-
nificantly different when compared by tumour grade (data not
shown).
IGFBP2 and MSLN as prognostic biomarkers
Linear models were developed to investigate the relationship of
IGFBP2 and MSLN levels to PDAC patient survival. In univariate
analyses, serum IGFBP2, serumMSLN, age, gender and class were
all significant predictors of survival (Table 2). In multivariate
analysis, age in IGFBP2 models, and M1 status in both IGFBP2
and MSLN models remained significant predictors of survival.
Adjusting for age, gender and class, serum IGFBP2 (P = 0.36) and
MSLN (P = 0.29) were no longer significant predictors of survival
(Table 2).Although adequately powered to detect the observed 2.0
hazard ratios in univariate interquartile range differences in the
data, the study was underpowered to detect the observed 1.2
hazard ratios in mutivariate interquartile range differences. Thus,
a larger study might reveal a prognostic potential for serum
IGFBP2 and MSLN.
Discussion
The diagnosis and management of PDAC is hampered by the
lack of effective biomarkers. The conventionally used PDAC
biomarker, CA 19-9, has limited diagnostic accuracy, is not syn-
thesized by about 10% of the population and is not specific for
PDAC as it is elevated in several gastrointestinal diseases.29 For
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Figure 3 Receiver-operating characteristics (ROC) curves for
IGFBP2 (a), MSLN (b) and CA 19-9 (c). Dotted lines indicate the
upper and lower 95% confidence levels. AUC = area under the curve
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these reasons, CA 19-9 is not used for screening but is commonly
employed to monitor disease progression and response to therapy.
In spite of extensive research, no single diagnostic biomarker has
emerged that is more effective than CA 19-9. Numerous combi-
nations of genetic lesions lead to PDAC development30 indicating
a high potential for variability in the molecular signatures in
different patients. This heterogeneity suggests that a panel of
biomarkers may be a more effective approach. It is in such a panel
that serum levels of IGFBP2 and MSLN, although independently
weak,may prove useful as a subset of cases showed elevated serum
levels. This idea is supported by the observation that IGFBP2 and
MSLN levels correctly identified samples that were misidentified
by CA 19-9.
In the context of a biomarkerpanel, co-expressedproteinswould
provide redundant diagnostic information. Based on the presence
of a cancer-related promoter element, MSLN and TIMP-1 have
been proposed to be transcriptionally co-regulated.26 However, in
our sample set,MSLN and TIMP-1 were not correlated suggesting
that any transcriptional co-regulation did not extend to circulating
serum levels. Thus, TIMP-1, which we previously showed to be
diagnostically useful,27may provide information supplementary to
MSLN in a biomarker panel.
Circulating MSLN was prognostic for survival in both gastric
and ovarian cancers,31,32 but MSLN serum levels were unrelated to
stage or survival in our PDAC sample set. The result that serum
MSLN was independent of PDAC stage is consistent with a pre-
vious report.25 When measured in tumour samples via tissue
microarray,MSLN levels in PDAC were predictive of early cancer-
caused mortality.33 Poor outcomes would be expected in highly
invasive disease and MSLN levels in PDAC tumours have been
clearly linked to increased invasiveness.14,15 Our results suggest
that, in PDAC, circulating MSLN is probably not related to tumor
levels. In contrast, IGFBP2 serum levels increased with increasing
stage in our sample set indicating a direct relationship with
tumour burden. As advanced stage disease correlates with poor
outcomes, it is unclear why IGFBP2 levels were not related to
survival, but it remains possible that a larger sample set will reveal
a significant relationship.
In summary, our study found that serum levels of IGFBP2
and MSLN were both significantly elevated in PDAC relative to
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Figure 4 Stage distribution of serum insulin-like growth factor binding protein 2 (IGFBP2) and mesothelin (MSLN) in pancreatic ductal
adenocarcinoma (PDAC) samples. Mean levels of IGFBP2 (a) and MSLN (b) at each stage are represented by the solid bars. Error bars
indicate a standard deviation. *P < 0.03 versus all other stages by ANOVA and Tukey–Kramer post-hoc test
Table 2 Univariate and multivariate analyses for factors affecting survival in pancreatic ductal adenocarcinoma (PDAC) cases (N = 84)
Predictor Level Hazard ratio Univariate P-value
(log-rank or Wald)
Multivariate P-value
(IGFBP2 model)
Multivariate P-value
(MSLN model)
IGFBP2 – 1.0015b < 0.0001 0.36a
MSLN – 1.015b 0.022 0.29a
Age at Sample – 1.031c 0.0057 0.039 0.053
Gender Female 1.00 (reference) (reference) (reference)
Male 0.5456 0.0090 0.30 0.23
Class N0 (reference) (reference) (reference)
N1 1.578 0.17 0.27 0.30
M1 6.436 <0.0001 <0.0001 <0.0001
aAdjusted for age, gender and class.
bPer unit change.
cPer year.
Bold numbers indicate statistically significant comparisons.
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non-cancer controls. Although individually weak diagnostic
biomarkers, serum levels of the proteins may prove useful when
combined with other biomarkers in a panel. Neither IGFBP2 nor
MSLN demonstrated prognostic accuracy in this sample popula-
tion although a study with a larger sample population may be
warranted.
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